$15.82 Million in Sales Expected for Recro Pharma Inc (REPH) This Quarter

Equities analysts expect Recro Pharma Inc (NASDAQ:REPH) to announce sales of $15.82 million for the current fiscal quarter, Zacks reports. Four analysts have issued estimates for Recro Pharma’s earnings. The highest sales estimate is $16.49 million and the lowest is $14.90 million. Recro Pharma reported sales of $19.04 million during the same quarter last year, which would suggest a negative year-over-year growth rate of 16.9%. The company is scheduled to issue its next earnings results on Tuesday, February 26th.

According to Zacks, analysts expect that Recro Pharma will report full year sales of $75.23 million for the current fiscal year, with estimates ranging from $74.46 million to $76.05 million. For the next fiscal year, analysts anticipate that the company will report sales of $85.65 million, with estimates ranging from $76.31 million to $102.00 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side analysts that follow Recro Pharma.

Recro Pharma (NASDAQ:REPH) last issued its earnings results on Wednesday, November 7th. The specialty pharmaceutical company reported ($0.64) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.67) by $0.03. Recro Pharma had a negative net margin of 79.42% and a negative return on equity of 220.42%. The company had revenue of $18.28 million during the quarter, compared to analysts’ expectations of $16.77 million.

REPH has been the subject of a number of research analyst reports. ValuEngine cut shares of Recro Pharma from a “buy” rating to a “hold” rating in a report on Tuesday, September 11th. Oppenheimer set a $18.00 target price on shares of Recro Pharma and gave the company a “buy” rating in a report on Wednesday, August 8th. Zacks Investment Research cut shares of Recro Pharma from a “buy” rating to a “hold” rating in a report on Saturday, November 10th. Piper Jaffray Companies set a $10.00 target price on shares of Recro Pharma and gave the company a “buy” rating in a report on Thursday, November 8th. Finally, Janney Montgomery Scott set a $13.00 target price on shares of Recro Pharma and gave the company a “buy” rating in a report on Monday, October 1st. Two research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Recro Pharma presently has a consensus rating of “Buy” and an average target price of $12.88.

Institutional investors and hedge funds have recently modified their holdings of the company. Oppenheimer & Co. Inc. purchased a new position in shares of Recro Pharma during the 2nd quarter worth approximately $154,000. Virtu Financial LLC purchased a new position in shares of Recro Pharma during the 3rd quarter worth approximately $156,000. Monarch Partners Asset Management LLC purchased a new position in shares of Recro Pharma during the 2nd quarter worth approximately $178,000. GSA Capital Partners LLP purchased a new position in shares of Recro Pharma during the 2nd quarter worth approximately $206,000. Finally, Alambic Investment Management L.P. increased its stake in shares of Recro Pharma by 378.0% during the 2nd quarter. Alambic Investment Management L.P. now owns 47,990 shares of the specialty pharmaceutical company’s stock worth $241,000 after purchasing an additional 37,950 shares in the last quarter. 52.20% of the stock is owned by institutional investors and hedge funds.

Shares of Recro Pharma stock opened at $7.07 on Thursday. Recro Pharma has a 12-month low of $4.78 and a 12-month high of $13.05. The company has a debt-to-equity ratio of 4.04, a current ratio of 1.36 and a quick ratio of 1.16. The stock has a market capitalization of $141.11 million, a price-to-earnings ratio of -3.55 and a beta of -0.51.

About Recro Pharma

Recro Pharma, Inc, a specialty pharmaceutical company, engages in developing non-opioid products for the treatment of acute pain primarily in the United States. The company's lead product candidate includes injectable meloxicam, which completed pivotal phase III clinical trials for the treatment of post-operative pain.

Featured Story: What are the Benefits of Index Funds?

Get a free copy of the Zacks research report on Recro Pharma (REPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Recro Pharma (NASDAQ:REPH)

Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply